

Tuesday, 27 March 10:05 ~ 11:10 / 13:10 ~ 17:35

Plenary Lecture: Room O Kanazawa Art Hall

Short Presentation for Invited Poster Presentation: Room O Kanazawa Art Hall

Invited Poster Presentation: Event Plaza in Basement of Kanazawa Station Motenashi Dome

第4回国際創薬シンポジウム ISMS

4th International Symposium for Medicinal Sciences (ISMS)

10:05 ~ 10:10

Opening Remark

Chairman: Akira OTAKA (Tokushima University)

10:10 ~ 11:10

Plenary Lecture 1

Chairman: Tohru FUKUYAMA (Nagoya University)

27O-ISMS-PL01 **Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites Including Human-Derived Natural Products**

Erick M. CARREIRA (Swiss Federal Institute of Technology Zurich)

13:10 ~ 14:10

Plenary Lecture 2

Chairman: Kentaro KOGURE (Tokushima University)

27O-ISMS-PL02 **Interfacing Nanomaterials with Biology: From Delivery of siRNA and CRISPR Machinery to Rapid Cell Phenotyping**

Vincent M. ROTELLO (Department of Chemistry, University of Massachusetts - Amherst)

14:15 ~ 17:35

Invited Poster Presentation

14:15 ~ 15:45 Short Presentation for Invited Poster Presentation (Room O)

15:55 ~ 17:35 Poster Presentation (Kanazawa Station Motenashi Dome)

Discussion Odd Number: 15:55 ~ 16:45

Even Number: 16:45 ~ 17:35

27O-ISMS01 Generation of Hepatocytes from Human ES/iPS Cells for Medicinal Sciences

○Kazuo TAKAYAMA¹, Hiroyuki MIZUGUCHI¹ (¹Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University)

27O-ISMS02 A Novel Long-Term Culture Method for Activating Cytochrome P450 and Liver-Specific Function of Hepatocytes Utilizing a Collagen Vitrigel Membrane Chamber

○Ryuji WATARI¹, Motoharu KAKIKI¹, Ayumi OSHIKATA², Toshiaki TAKEZAWA², Chihiro YAMASAKI³, Yuji ISHIDA³, Chise TATENO³, Yukie KURODA⁴, Seiichi ISHIDA⁴, Kazutomi KUSANO¹ (¹Drug Metabolism and Pharmacokinetics Tsukuba, Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., ²Division of Biotechnology, Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, ³R&D department, PhoenixBio, Co., Ltd., ⁴Division of Pharmacology, National Institute of Health Sciences)

27O-ISMS03 Translational Research in Drug Development for NASH Using a Cell-based Chemical Screening

○Yusuke HIRATA¹, Atsushi MATSUZAWA¹ (¹Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University)

27O-ISMS04 The Profiles of Trastuzumab Deruxtecan (DS-8201a), Topoisomerase I Inhibitor Exatecan-Derivative Based HER2-Targeting Antibody-Drug Conjugate

○Takashi NAKADA¹, Hiroyuki NAITO¹, Yusuke OGITANI¹, Takahiro JIKOH¹, Koji MORITA¹, Tomomi NAKAYAMA-IWATA¹, Chiaki ISHII¹, Junko YAMAGUCHI¹, Takeshi MASUDA¹, Ryo ATSUMI¹, Katsunobu HAGIHARA¹, Masataka OITATE¹, Yoshihiko FUJISAKI¹, Takeshi HONDA¹, Yuki ABE¹, Toshinori AGATSUMA¹ (¹Daiichi Sankyo Co., Ltd.)

- 27O-ISMS05 Endogenous Simian Retrovirus Variations in Vero Cells: Implications for Quality Control of a Human Vaccine Cell Substrate
Chisato SAKUMA¹, Tsuyoshi SEKIZUKA², Makoto KURODA², Fumio KASAI³, Kyoko SAITO¹, Masaki IKEDA⁴, Toshiyuki YAMAJI¹, Naoki OSADA⁴, ○Kentaro HANADA¹ (¹Department of Biochemistry & Cell Biology, National Institute of Infectious Diseases, ²Pathogen Genomics Center, National Institute of Infectious Diseases, ³Laboratory of Cell Cultures, National Institutes of Biomedical Innovation, Health and Nutrition, ⁴Graduate School of Information Science and Technology, Hokkaido University)
- 27O-ISMS06 Differential Infection Pattern of AAVs in Mouse Retina
○Tesshu HORI^{1,2}, Masashi FUKUTOME^{2,3}, Chiseto MAEJIMA^{1,2}, Satoru MORITOH^{2,4}, Kenta KOBAYASHI⁵, Chieko KOIKE^{1,2,6,7} (¹College of Pharmaceutical Sciences, ²Laboratory for Systems Neurosciences and Developmental Biology, ³College of Life Sciences, ⁴Ritsumeikan Global Innovation Research Organization (R-GIRO), Ritsumeikan University, ⁵National Institute for Physiological Sciences, ⁶Graduate School of Life Sciences, ⁷Center for Systems Vision Science, Organization of Science and Technology, Ritsumeikan University)
- 27O-ISMS07 ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor, in the Treatment of Allergic Disease
○Mako NUMAZAKI¹, Kaori HANAOKA¹, Emiko IMAMURA¹, Masashi MAEDA¹, Kazunori ARAI¹, Tetsu SAITO¹, Fujiko TAKAMURA¹, Hiroshi SUZUKI¹, Satoshi KUBO¹, Shigetada FURUKAWA¹ (¹Drug Discovery Research, Astellas Pharma Inc.)
- 27O-ISMS08 Treatment of Ischemic Stroke by Combination Therapy with Liposomal Neuroprotectants and Tissue Plasminogen Activator
○Tatsuya FUKUTA^{1,2}, Tomohiro ASAI², Kentaro KOGURE¹, Naoto OKU² (¹Department of Pharmaceutical Health Chemistry, Graduate School of Biomedical Sciences, Tokushima University, ²Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka)
- 27O-ISMS09 Responsive Nanocaplets Prepared via ‘Oxidative Polymerization’ for Intracellular Delivery of Anionic Proteins
○P.K HASHIM¹, Kou OKURO¹, Takuzo AIDA¹ (¹School of Engineering, Department of Chemistry and Biotechnology, The University of Tokyo)
- 27O-ISMS10 Controlled Release of Anticancer Drugs by LSD1 Inhibition
○Yosuke OTA¹, Yukihiko ITOH¹, Takayoshi SUZUKI¹ (¹Graduate School of Medical Science, Kyoto Prefectural University of Medicine)
- 27O-ISMS11 Prediction of Human Pharmacokinetics Using Chimeric Mice with Humanized Liver
○Yoichi NARITOMI¹, Seigo SANOH², Shigeru OHTA² (¹Analysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc., ²Graduate School of Biomedical and Health Sciences, Hiroshima University)
- 27O-ISMS12 Natural Product Discovery by Heterologous Expression of Cryptic Biosynthetic Pathway in *Aspergillus oryzae*
○Teigo ASAI¹ (¹Department of Life Sciences, Graduate school of Arts and Sciences, The University of Tokyo)
- 27O-ISMS13 Plecomarcolide Analogues Produced by Streptomyces sp. GIC10-1 Isolated from a Marine Sponge *Theonella* sp.
Yu-Hsin CHEN^{1,2}, Mei-Chin LU^{2,3}, Ching-Feng WENG¹, Jimmy KUO^{2,3}, ○Ping-Jyun SUNG^{2,3} (¹Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, ²National Museum of Marine Biology and Aquarium, ³Graduate Institute of Marine Biology, National Dong Hwa University)
- 27O-ISMS14 Bioinspired Chemical Synthesis of Monomeric and Dimeric Stephacidin A Congeners
Ken MUKAI¹, Danilo PEREIRA DE SANT’ANA¹, ○Yasuo HIROOKA², Eduardo V. MERCADO-MARIN¹, David E. STEPHENS¹, Kevin G. M. KOU¹, Sven C. RICHTER¹, Naomi KELLEY¹, Richmond SARPONG¹ (¹Department of Chemistry, University of California, Berkeley, ²Ono Pharmaceutical Co., Ltd., Medicinal Chemistry Research Laboratories)
- 27O-ISMS15 Discovery of a Novel Inhibitor (ASP8273) of EGFR T790M Mutation
○Maiko IIDA¹, Takahiro MATSUYA¹, Itsuro SHIMADA¹, Shigetoshi KIKUCHI¹, Kenichi ONDA¹, Hiroaki TANAKA¹, Naoki KANEKO¹, Hideki SAKAGAMI¹, Nobuaki SHINDO¹, Shinya MIMASU¹, Yoichi NARITOMI¹, Yosuke YAMANAKA¹, Tadashi TERASAKA¹, Masaaki HIRANO¹ (¹Astellas Pharma Inc.)

- 27O-ISMS16 Identification of Selective TRPM8 Antagonists for the Treatment of Neuropathic Pain
 ○Masashi OHMI¹, Yuji SHISHIDO¹, Kazuo ANDO¹, Kiyoshi KAWAMURA¹, Hiroyuki OHSHIRO¹, Akiyoshi FUJIUCHI¹, Akiko YAMADA¹, Norikazu GAJA¹, Azusa SATO¹, Yumi ISOGAI¹, Shuzo WATANABE¹ (¹RaQualia Pharma Inc.)
- 27O-ISMS17 Synthetic Posttranslational Modifications: A Chemical Catalyst System to Directly Introduce Posttranslational Modifications into Endogenous Chromatin
 ○Kenzo YAMATSUGU^{1,2}, Yoshifumi AMAMOTO^{1,2}, Yuki AOI^{1,2}, Nozomu NAGASHIMA¹, Hiroki SUTO^{1,2}, Daisuke YOSHIDOME³, Yasuhiro ARIMURA⁴, Akihisa OSAKABE⁴, Daiki KATO⁴, Hitoshi KURUMIZAKA⁴, Shigehiro A. KAWASHIMA^{1,2}, Motomu KANAI¹ (¹Graduate School of Pharmaceutical Sciences, The University of Tokyo, ²JST-ERATO, ³Schrödinger K. K., ⁴Laboratory of Structural Biology, Graduate School of Advanced Science and Engineering, Waseda University)
- 27O-ISMS18 Design and Synthesis of a Neuromedin U Receptor 2-selective PEGylated Peptide with Potent Body Weight-Lowering Effect
 ○Yoko KANEMATSU¹, Naoki NISHIZAWA¹, Tomoko KAISHO¹, Hiroaki NAGAI¹, Taisuke MOCHIDA¹, Tomoko ASAKAWA¹, Hiroshi INOOKA¹, Katsuko DOTE¹, Hisashi FUJITA¹, Kouta MATSUMIYA¹, Hideaki HIRABAYASHI¹, Junichi SAKAMOTO¹, Tetsuya OHTAKI¹, Shiro TAKEKAWA¹, Taiji ASAMI¹ (¹Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.)
- 27O-ISMS19 Development of Glycosylated Somatostatin Having Native-like Activity and Prolonged Half-life
 ○Hirofumi OCHIAI¹, Hayato SAIJO¹, Takahiro YAMAMOTO¹, Yuji NISHIUCHI¹, Akio KANATANI¹, Taiji SHIMODA¹ (¹GlyTech, Inc.)
- 27O-ISMS20 Innovative Synthesis Technology for the Substances of Peptide Therapeutics
 ○Daisuke KUBO¹, Kazuaki KANAI¹, Rino ARAKI¹, Seiji NUKUI¹, Shuji FUJITA¹, Yu ITO¹ (¹Jitsubo Co., Ltd.)
- 27O-ISMS21 In Vivo Protein Knockdown by Chimeric Small-compound SNIPERs
 ○Nobumichi OHOKA¹, Yoko MORITA², Katsunori NAGAI², Kenichiro SHIMOKAWA², Osamu UJIKAWA², Ikuo FUJIMORI², Masahiro ITO², Youji HAYASE², Keiichiro OKUHIRA¹, Norihito SHIBATA¹, Takayuki HATTORI¹, Tomoya SAMEJIMA², Osamu SANO², Ryokichi KOYAMA², Yasuhiro IMAEDA², Hiroshi NARA², Nobuo CHO², Mikihiko NAITO¹ (¹Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, ²Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.)
- 27O-ISMS22 Development of Protein Degradation Inducers of Oncogenic BCR-ABL Protein by Conjugation of ABL Kinase Inhibitors and IAP Ligands
 ○Norihito SHIBATA¹, Naoki MIYAMOTO², Katsunori NAGAI², Kenichiro SHIMOKAWA², Tomoya SAMESHIMA², Nobumichi OHOKA¹, Takayuki HATTORI¹, Yasuhiro IMAEDA², Hiroshi NARA², Nobuo CHO², Mikihiko NAITO¹ (¹Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, ²Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.)
- 27O-ISMS23 DFP-11207, a Novel Promising Antimetabolite by Using the Technology of Module Drug Discovery
 ○Masakazu FUKUSHIMA¹, Kenzo IIZUKA¹, Kokoro ESHIMA¹, Chung ZHANG¹, Cheng JIN¹, Kiyoshi ESHIMA¹ (¹Division of Research and Development, Delta-Fly Pharma, Inc.)
- 27O-ISMS24 Similarity Implicated Exploration of the Fragment Galaxy
 Gábor IMRE¹, Ákos TARCSAY¹, ○Fumiaki ARUGA² (¹ChemAxon Ltd., ²Patcore, Inc.)
- 27O-ISMS25 Machine Learning Techniques for Peptide Optimization from Sequence Information
 Mark R. HANSEN¹, Evgenia RAZUMOVSKAYA¹, Jason HODGES¹, Hugo O VILLAR¹, ○Fumiaki ARUGA² (¹Altoris, Inc., ²Patcore, Inc.)
- 27O-ISMS26 Construction of a Novel System for the Prediction of Major Clearance Pathways of Drugs only from Their 2D Chemical Descriptors
 ○Kazuya MAEDA¹, Naomi WAKAYAMA², Kota TOSHIMOTO^{3,4}, Shun HOTTA³, Takashi ISHIDA³, Yutaka AKIYAMA³, Yuichi SUGIYAMA⁴ (¹Graduate School of Pharmaceutical Sciences, the University of Tokyo, ²Eisai Co., Ltd., ³Graduate School of Information Science and Engineering, Tokyo Institute of Technology, ⁴Sugiyama Laboratory, RIKEN Cluster for Industry Partnerships, RIKEN)

- 27O-ISMS27 [Cancelled]
- 27O-ISMS28 Establishment of a Unique Bio-conversion Platform for Drug Discovery
 ○Shinya OKUBO¹, Tomoyuki SHIBUGUCHI², Eri ENA³, Akifumi OKUDA¹ (¹Technology Cross Point Laboratory, hhc Data Creation Center, Eisai Co., Ltd., ²Neurology Tsukuba Research Department, Discovery, Medicine Creation, Neurology Business Group, Eisai Co., Ltd., ³Analytical Research. Pharmaceutical Science & Technology Core Function Unit, Medicine Development Center, Eisai Co., Ltd.)
- 27O-ISMS29 A NGS-based Liquid Biopsy Gene Panel Assay with Molecular Barcode Technology
 ○Yoshiharu SATO¹, Yoji KUKITA², Ryo MATOBA¹, Kikuya KATO² (¹DNA Chip Research Inc., ²Laboratory of Medical Genomics, Nara Institute of Science and Technology)
- 27O-ISMS30 Evaluation of Time Resolution in Mice Operant Learning System
 ○Mami OIKAWA^{1,2}, Yuichiro NOMURA^{2,3}, Syohei IKUTA^{1,2}, Daiki HORIE^{2,4}, Akira AMANO^{4,5}, Kazuhiro SHIMONOMURA^{5,6}, Yasuhiro SEYA^{5,7}, Chieko KOIKE^{1,2,3,5} (¹Grad. Sch. of Life Sciences, ²Lab. for Systems Neurosciences and Developmental Biol., ³Col. of Pharmaceut. Sci., ⁴Col. of Life Sci., ⁵Ctr. for Systems Vision Sci., ⁶Col. of Sci. and Engin., Ritsumeikan Univ., ⁷Fac. of Human Informatics, Aichi Shukutoku Univ.)
- 27O-ISMS31 Development of Highly Stereoselective Synthetic Method for 3-amino-4-hydroxytetrahydropyran via Transfer Hydrogenation
 ○Kazuki AZUMA¹, Sayuri HIRANO¹, Masatoshi YAMADA¹, Etsuo KOTANI¹, Takahiro KONISHI¹, Mitsuhsa YAMANO¹ (¹Chemical R&D Division, SPERA PHARMA, Inc.)
- 27O-ISMS32 Rapid and Efficient Synthesis of Deuterated Cyclobutane Derivatives Using Continuous Photo Flow Chemistry
 ○Toshiro YAMASHITA¹, Hitoaki NISHIKAWA¹, Tetsuji KAWAMOTO¹ (¹Chemistry, Research Division, Axcelead Drug Discovery Partners, Inc.)
- 27O-ISMS33 Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors
 ○Fumiyuki SHIRAI¹, Yasuko KODA¹, Kenichi WASHIZUKA¹, Nobuko YOSHIMOTO¹, Hiroo KOYAMA¹, Takehiro FUKAMI¹, Yoko YASHIRODA¹, Minoru YOSHIDA¹, Hitomi YUKI¹, Hirofumi WATANABE¹, Teruki HONMA¹, Hideaki NIWA¹, Shin SATO¹, Takashi UMEHARA¹, Mikako SHIROUZU¹, Yukiko MURAMATSU², Haruka YOSHIDA², Anna MIZUTANI², Hiroyuki SEIMIYA² (¹RIKEN Center for Life Science Technologies, ²Cancer Chemotherapy Center, Japanese Foundation for Cancer Research)
- 27O-ISMS34 Identification of Bis-heteroaryl Pyrazoles as Potent ALK2 (R206H) Inhibitors for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
 ○Katsuhiko SEKIMATA¹, Tomohiro SATO², Naoki SAKAI³, Hisami WATANABE³, Chiemi MISHIMATSUMAGARI³, Tomonori TAGURI¹, Takehisa MATSUMOTO³, Noriko HANDA⁴, Teruki HONMA², Akiko TANAKA³, Mikako SHIROUZU³, Shigeyuki YOKOYAMA⁴, Yoshinobu HASHIZUME⁵, Kohei MIYAZONO⁶, Hiroo KOYAMA¹ (¹Drug Discovery Chemistry Platform Unit, RIKEN Center for Life Science Technologies, ²Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Life Science Technologies, ³Drug Discovery Structural Biology Platform Unit, RIKEN Center for Life Science Technologies, ⁴Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center, ⁵RIKEN Program for Drug Discovery and Medical Technology Platforms, ⁶Department of Molecular Pathology, Graduate School, The University of Tokyo)
- 27O-ISMS35 Identification of Novel Pyrrolo[2,3-*d*]pyrimidine Derivatives as Potent HCK and FLT3-ITD Dual Inhibitors
 ○Yasuko KODA¹, Ko KIKUZATO¹, Junko MIKUNI², Akiko TANAKA², Hitomi YUKI³, Teruki HONMA³, Yuri TOMABECHI², Mutsuko KUKIMOTO-NIINO², Mikako SHIROUZU², Fumiyuki SHIRAI¹, Hiroo KOYAMA¹ (¹Drug Discovery Chemistry Platform Unit, RIKEN Center for Life Science Technologies, ²Drug Discovery Structural Biology Platform Unit, RIKEN Center for Life Science Technologies, ³Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Life Science Technologies)
- 27O-ISMS36 Unstructured Protein: A New Approach for Drug Discovery by Natural Product Templates
 Hiroyuki KOUJI¹, ○Akira KATOH¹ (¹Translational Chemical Biology Laboratory, Faculty of Medicine, Oita University)
- 27O-ISMS37 S-033188: A Novel, First-in-Class, Orally Bioavailable Cap-dependent Endonuclease Inhibitor of Influenza
 ○Masayoshi MIYAGAWA¹, Toshiyuki AKIYAMA¹, Yoshiyuki TAODA¹, Kenji TAKAYA¹, Takao SHISHIDO¹, Ryu YOSHIDA¹, Makoto KAWAI¹ (¹Shionogi & Co., Ltd.)

- 27O-ISMS38 Discovery of Novel 1,3-Oxazine BACE1 (β -Secretase) Inhibitors: Incorporation of an Olefin Bond to Mitigate P-gp Efflux Leading to Robust A β Reduction
 ○Kouki FUCHINO¹, Yasunori MITSUOKA¹, Moriyasu MASUI¹, Syuhei YOSHIDA¹, Kazuo KOMANO¹, Noriyuki KUROSE¹, Takahiko YAMAMOTO¹, Chie UNEMURA¹, Motoko HOSONO¹, Hisanori ITO¹, Gaku SAKAGUCHI¹, Shigeru ANDO¹, Shuichi OHNISHI¹, Yasuto KIDO¹, Kiyotaka KOYABU¹, Tamio FUKUSHIMA¹, Herman BORGHYS², Harrie GIJSEN², Yasuyoshi ISO¹, Ken-ichi KUSAKABE¹
 (¹Shionogi & Co., Ltd., ²Janssen Pharmaceutica NV)
- 27O-ISMS39 Aurano-fin, an Inhibitor of Thioredoxin Reductase, Exhibits Preferential Cytotoxicity Under Nutrient-deprived Conditions in Human Pancreatic Cancer Cells
 ○Takefumi ONODERA¹, Isao MOMOSE¹, Manabu KAWADA^{1,2} (¹Institute of Microbial Chemistry (BIKAKEN), Numazu, ²Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology)
- 27O-ISMS40 Discovery of Evocalcet, a Next Generation Calcium-Sensing Receptor Agonist for the Treatment of Hyperparathyroidism
 ○Hiroshi MIYAZAKI¹, Yousuke IKEDA¹, Yasunori MORITANI¹, Osamu SAKURAI¹, Tsutomu MIYAKE¹, Rie TSUBOTA¹, Jyunko OKABE¹, Masataka KURODA¹, Yutaka HISADA¹, Tetsuya YANAGIDA¹, Hikaru YONEDA¹, Rikiya OHASHI¹, Hajime FUKUDA¹, Koki KOJIMA¹, Takayuki KIFUJI¹, Naoya SATO¹, Akiko IDEI¹, Taku IGUCHI¹, Tetsuya SAKAIRI¹, Takehisa KAWATA², Shin TOKUNAGA² (¹Mitsubishi Tanabe Pharma Corporation, ²Kyowa Hakko Kirin Co., Ltd.)
- 27O-ISMS41 Development of Novel Non-fibrate PPAR α Activator for Metabolic Diseases
 ○Keisuke TACHIBANA¹, Tomohiro YUZURIHA¹, Ryotaro TABATA¹, Syohei FUKUDA¹, Kazuto NUNOMURA¹, Tadayuki KOBAYASHI¹, Kenji ISHIMOTO¹, Hiroyuki MIYACHI², Takefumi DOI¹
 (¹Graduate School of Pharmaceutical Sciences, Osaka University, ²Lead Exploration Unit, Drug Discovery Initiative, The University of Tokyo)
- 27O-ISMS42 Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitor T-3764518 as Anticancer Agent
 ○Keisuke IMAMURA¹, Naoki TOMITA¹, Youichi KAWAKITA¹, Yoshiteru ITO¹, Kouji ONO¹, Noriyuki NII¹, Tohru MIYAZAKI¹, Kazuko YONEMORI¹, Michiko TAWADA¹, Hiroyuki SUMI¹, Yoshihiko SATOH¹, Yukiko YAMAMOTO¹, Ikuo MIYAHISA¹, Masako SASAKI¹, Yoshinori SATOMI¹, Megumi HIRAYAMA¹, Ryuichi NISHIGAKI¹, Hironobu MAEZAKI¹ (¹Takeda Pharmaceutical Company Ltd.)
- 27O-ISMS43 Synthesis and Mechanistic Studies of Biakamides, Naturally-occurring Anti-austerity Agents Targeting Mitochondria
 Ryosuke ISHIDA¹, Hirokazu MATSUMOTO¹, Sayaka ICHII¹, Masayoshi ARAI¹, Motomasa KOBAYASHI¹,
 ○Naoyuki KOTOKU^{1,2} (¹Graduate School of Pharmaceutical Sciences, Osaka University, ²College of Pharmaceutical Sciences, Ritsumeikan University)